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Abstract
Eye phenotypes were investigated in Le-CreTg/2; Pax6fl/+ mice, which were expected to show tissue-specific reduction of
Pax6 in surface ectoderm derivatives. To provide a better comparison with our previous studies of Pax6+/2 eye phenotypes,
hemizygous Le-CreTg/2 and heterozygous Pax6fl/+mice were crossed onto the CBA/Ca genetic background. After the Le-Cre
transgene had been backcrossed to CBA/Ca for seven generations, significant eye abnormalities occurred in some
hemizygous Le-CreTg/2; Pax6+/+ controls (without a floxed Pax6fl allele) as well as experimental Le-CreTg/2; Pax6fl/+ mice.
However, no abnormalities were seen in Le-Cre2/2; Pax6fl/+ or Le-Cre2/2; Pax6+/+ controls (without the Le-Cre transgene). The
severity and frequency of the eye abnormalities in Le-CreTg/2; Pax6+/+ control mice diminished after backcrossing Le-CreTg/2
mice to the original FVB/N strain for two generations, showing that the effect was reversible. This genetic background effect
suggests that the eye abnormalities are a consequence of an interaction between the Le-Cre transgene and alleles of
unknown modifier genes present in certain genetic backgrounds. The abnormalities were also ameliorated by introducing
additional Pax6 gene copies on a CBA/Ca background, suggesting involvement of Pax6 depletion in Le-CreTg/2; Pax6+/+ mice
rather than direct action of Cre recombinase on cryptic pseudo-loxP sites. One possibility is that expression of Cre
recombinase from the Pax6-Le regulatory sequences in the Le-Cre transgene depletes cofactors required for endogenous
Pax6 gene expression. Our observation that eye abnormalities can occur in hemizygous Le-CreTg/2; Pax6+/+ mice, in the
absence of a floxed allele, demonstrates the importance of including all the relevant genetic controls in Cre-loxP
experiments.
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Introduction
Tg(Pax6-cre,GFP)1Pgr transgenic mice (hereafter abbreviated
to Le-Cre transgenic mice) express Cre recombinase from Pax6-Le
tissue-specific regulatory elements (the Pax6 surface ectoderm
enhancer and P0 promoter) in the pancreas and developing head
surface ectoderm from embryonic day (E) 8.75 [1]. In their
original study, Ashery-Padan et al. produced Le-CreTg/2; Pax6fl/
lacZ mice, which were hemizygous for the Le-Cre transgene and
carried both the Pax6lacZ null and floxed Pax6fl alleles [1]. Pax6
was deleted in the head surface ectoderm lineage early in
development, demonstrating that, in the absence of Pax6, the
lens fails to develop and the optic cup develops abnormally.
Subsequently Le-Cre transgenic mice have been widely used to
delete floxed alleles of other genes in the developing surface
ectoderm including Tfap2a [2], Fgfr2 [3], Ctnnb (previously
Catnb; b-catenin) [4], Six3 [5], Klf4 [6,7], Klf5 [8,9], Pnn [10],
Spry1 and Spry2 [11], Rac1 [12], Ndst1 (in a Ndst22/2
background) [13], Ilk [14], Vegfa [15] and Cited2 (either alone
or in combination with floxed Vegfa or floxed Hif1a) [16,17,18].
We conditionally excised a single Pax6 allele in the head surface
ectoderm and derivatives (lens, conjunctiva and corneal epitheli-
um) of Le-CreTg/2; Pax6fl/+ mice to reduce Pax6 levels in these
tissues rather than completely delete it. Pax6 levels are reduced
globally in Pax6+/2 mice, which are heterozygous for any Pax62
null allele (e.g. Pax6+/Sey or Pax6+/Sey-Neu). This global reduction
results in a complex combination of abnormal phenotypes in the
fetal and adult cornea, which disrupts corneal homeostasis
[19,20,21,22] and affects wound healing [23,24]. We aimed to
analyse the consequences of tissue-specific depletion of Pax6 on
the corneal phenotype and compare this to the previously reported
consequences of globally reducing Pax6 levels in Pax6+/2
heterozygotes, thereby distinguishing abnormalities caused by
low levels of Pax6 in the surface ectoderm lineage from those
caused by low levels of Pax6 in other tissues, such as the optic cup.
As the lens produces growth factors and probably influences the
development of other anterior segment tissues [25,26], we
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anticipated that depletion of Pax6 in the surface ectoderm tissues
might also affect neighbouring tissues not derived from this
lineage. This could occur if reduced Pax6 affected the production
of signalling molecules or if Pax6 was itself secreted extracellularly,
as reported for the developing chick nervous system [27].
Two previous studies used a similar approach and showed that
reducing Pax6 levels in the surface ectoderm of Le-CreTg/2; Pax6fl/
+ eyes was sufficient to produce a number of developmental
abnormalities that are characteristic of Pax6+/2 heterozygotes.
Some of these directly affected the lens and corneal epithelium
(e.g. the lens was small and often remained attached to the cornea),
suggesting an autonomous requirement for normal Pax6 gene
dosage during development of these tissues [28]. However, other
abnormalities suggested that normal Pax6 gene dosage in the
surface ectoderm tissues is also required for normal development
of some neighbouring tissues, implying a non-cell-autonomous
mode of action. The trabecular meshwork and Schlemm’s canal
failed to develop and adhesions occurred between the peripheral
iris and cornea causing the iridocorneal angle to be closed in the
adult Le-CreTg/2; Pax6fl/+ eye [29]. These abnormalities suggest
that reduced Pax6 gene dosage in the surface ectoderm tissues can
cause abnormalities in the neighbouring ocular mesenchyme.
We planned to extend these experiments and use Le-CreTg/2;
Pax6fl/+ eyes with a panel of morphological, immunohistochemical
and wound-healing endpoints to consider a wider range of
abnormal corneal phenotypes, as previously reported for adult
Pax6+/2 heterozygotes. To allow direct comparisons with pheno-
types in our previous studies of Pax6+/2 mice on a predominantly
CBA/Ca genetic background, we crossed the Le-Cre transgene
onto this genetic background. After several generations, some
hemizygous Le-CreTg/2; Pax6+/+ control mice had eye abnormal-
ities even though they did not carry a floxed Pax6fl allele.
Although eye abnormalities have been observed in homozygous
Le-CreTg/Tg mice on some genetic backgrounds, this has only been
reported as a brief abstract [30] and we are not aware of any
previous reports of eye abnormalities in hemizygous Le-CreTg/2
mice. The unexpected control phenotype in our study was only
identified because all three genetic controls (Le-CreTg/2; Pax6+/+,
Le-Cre2/2; Pax6fl/+ and Le-Cre2/2; Pax6+/+) were examined
alongside experimental Le-CreTg/2; Pax6fl/+ eyes throughout the
experiment, as the genetic background changed.
We have characterised the eye defects in Le-CreTg/2; Pax6+/+
mice so that others are aware of the genetic background issues with
the Le-Cre transgene. It is possible that some previous reports of
Le-Cre-mediated conditional gene deletions may have conflated
the abnormal eye phenotypes, resulting from a deleted floxed
gene, with unexpected abnormal phenotypes, arising from effects
of the Le-Cre transgene itself.
Materials and Methods
Ethics Statement
All the animal work in this study was approved by the
University of Edinburgh Ethical Review Committee (applications
PL21–06 and PL26–11) and performed in accordance with UK
Home Office regulations under project license numbers PPL 60/
3635 and PPL 60/4302. Mice were killed by cervical dislocation
following inhalation of gaseous isoflurane anaesthetic. The highest
standards of animal care were maintained throughout the study.
Experimental animals
FVB/N mice were purchased from Charles River UK and
other mice were bred and maintained in the Biomedical Research
Facilities of the University of Edinburgh. Heterozygous Pax6t-
m1Ued/+ (abbreviated to Pax6fl/+) mice [31] were obtained from
Prof David Price (University of Edinburgh, UK) on an outbred
CD1 genetic background. Hemizygous Le-CreTg/2 mice (full name
Tg(Pax6-cre,GFP)1Pgr; MGI number 3045749) [1] were ob-
tained from Dr Ruth Ashery-Padan and Prof Peter Gruss (Max
Plank Institute for Biophysical Chemistry, Goettingen, Germany)
on an inbred FVB/N genetic background. (We use the genotype
notation Le-CreTg/Tg to represent mice homozygous for the Le-Cre
transgene, Le-CreTg/2 for hemizygous mice and Le-Cre2/2 for
mice without the transgene.) We crossed both stocks to CBA/Ca
to make the genetic background more consistent with our previous
studies with Pax6+/2 (Pax6+/Sey-Neu) mice. (Unlike CBA/J, FVB/N
and some CD1 mice, the CBA/Ca inbred strain does not carry the
Pde6brd1 retinal degeneration mutation.) Le-CreTg/2; Pax6+/+and
Le-Cre2/2; Pax6fl/+ mice were intercrossed to produce offspring of
four genotypes, with or without the Le-Cre transgene and with or
without the Pax6fl floxed allele of Pax6: (i) Le-CreTg/2; Pax6fl/+,
(ii) Le-CreTg/2; Pax6+/+, (iii) Le-Cre2/2; Pax6fl/+ and (iv) Le-Cre2/
2; Pax6+/+ (which is wild-type, WT). For the initial crosses (stage
1), the Le-CreTg/2 mice used had been crossed to CBA/Ca for 3 or
4 generations (denoted as N3–N4) and the Pax6fl/+ mice had been
crossed to CBA/Ca for 1 or 2 generations. The average genetic
background of the stage-1 progeny was estimated as approxi-
mately 78% CBA/Ca, 5% FVB and 17% CD1 (Table S1 and
Fig. 1A). Wound healing studies were undertaken with stocks that
had been backcrossed to CBA/Ca for a few more generations (Le-
CreTg/2 at N6; Pax6fl/+ at N3). This is designated stage 2 and the
average genetic background was estimated as approximately 93%
CBA/Ca, 0.8% FVB and 6% CD1 (Table S1 and Fig. 1B).
Further investigations of embryonic day (E)12.5 fetal stages to
postnatal day (P) 10 and adults were undertaken in stage 3 after
further backcrossing (Le-CreTg/2 at N7-N8; Pax6fl/+ at N5–N6).
The average genetic background of the stage-3 progeny was
estimated as approximately 98% CBA/Ca; 0.3% FVB and 1.5%
CD1 (Table S1 and Figs. 1C,D). A final comparison (stage 4) was
made using Le-CreTg/2 mice that had been backcrossed to CBA/
Ca for 8 generations and then crossed to FVB/N for 2 generations
to change the genetic background and Pax6fl/+ mice that had been
crossed to CBA/Ca for 5 or 6 generations. The average genetic
background of the stage-4 progeny was estimated as approxi-
mately 61% CBA/Ca, 38% FVB and 1.2% CD1 (Table S1 and
Fig. 1F). Mice were genotyped by polymerase chain reaction
(PCR) [1,31]. The study was conducted continuously, Le-Cre mice
used were all derived from a single backcross line and mice were
bred from June 2010 to October 2012 as shown in Table S1.
Experiments were all performed by the same person (NJD), using
the same methods throughout the study.
Heterozygous Pax6+/Sey-Neu mice (abbreviated to Pax6+/2) were
maintained by crossing them to inbred CBA/Ca mice and were
considered congenic on that strain (.20 backcross generations).
Heterozygotes were distinguished from wild-type littermates by
eye size and genotypes were confirmed by PCR [32]. Mice
carrying the PAX77 transgene, comprising 5–7 copies of the
human PAX6 gene [33] were obtained from Prof Veronica van
Heyningen and Dr Dirk A. Kleinjan (MRC Human Genetics
Unit, Edinburgh) on an outbred CD1 genetic background. (We
use the genotype notation PAX77Tg/Tg to represent mice
homozygous for the PAX77 transgene, PAX77Tg/2 for hemizy-
gous mice and PAX772/2 for mice without the transgene.)
Hemizygous PAX77Tg/2 mice used in this study had been
backcrossed to the CBA/Ca genetic background for at least 20
generations (CBA/Ca-PAX77Tg/2 congenic strain) and were
identified by their small eye size with genotypes confirmed by
PCR as described previously [34,35]. The genetic background of
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Le-CreTg/2; Pax6fl/+ mice used for crosses with CBA/Ca-
PAX77Tg/2 (Le-CreTg/2 at N6; Pax6fl/+ at N5) was approximately
98% CBA, 0.4% FVB and 1.6% CD1), which is equivalent to
stage-3 mice, and the genetic background of mice produced by the
Le-CreTg/2; Pax6fl/+6PAX77Tg/2 cross was estimated as approx-
imately 99% CBA/Ca, 0.2% FVB/N and 0.8% CD1 (Table S1
and Fig. 1G). Z/AP reporter mice express lacZ in all tissues but
after recombination of loxP sites, lacZ is deleted and human
placental alkaline phosphatase (AP) is expressed [36]. Z/AP mice
were obtained on an outbred CD1 genetic background from Prof.
David Price (University of Edinburgh, UK), crossed to CBA/Ca
and genotyped, using PCR to detect the lacZ region of the Z/AP
construct. The genetic background of mice produced by Le-
CreTg6Z/AP crosses was estimated as approximately 97% CBA/
Ca, 0.8% FVB/N and 2.3% CD1 (Table S1 and Fig. 1E) and is
considered equivalent to the stage 3 genetic background.
Adult mice were killed by cervical dislocation, following
inhalation of gaseous isoflurane anaesthetic, at 12 weeks and their
eyes were removed immediately, weighed and fixed in 4%
paraformaldehyde (PFA). For wound-healing studies, eyes were
wounded in situ and removed for organ culture. For postnatal day
(P) 2 and P10 samples, the day of birth was defined as P0 and
samples were collected and fixed in 4% PFA. For embryonic
stages, the morning that a vaginal plug was found was defined as
embryonic day (E) 0.5; embryos were collected and heads were
removed and fixed in 4% PFA. Only one eye per mouse (the right
eye) was examined histologically or by immunohistochemistry so
the numbers of eyes examined is also equal to the numbers of mice
examined.
Histology
Samples were fixed in 4% PFA overnight at 4uC, processed to
wax and 7 mm sections cut. Adult eyes were cut in an anterior-
posterior plane to include cornea, lens and retina. To avoid adult
lenses shattering the wax block was kept wet during sectioning.
Embryonic heads were cut anterior-posterior in a horizontal plane
so sections through the developing eye included cornea, lens, and
retina. Histological features were compared using standard
haematoxylin and eosin (H & E) staining methods. For Periodic
acid-Schiff’s (PAS) staining, slides were washed in periodic acid for
15 minutes, rinsed in water and transferred to Schiff’s reagent for
5 minutes.
Morphometric measurements
Corneal diameters were measured using a stereomicroscope
fitted with an eyepiece graticule. Tissue sections of adult eyes were
viewed under a Zeiss Axioplan 2 compound microscope (x 40
objective) and captured images of the cornea measured using a
calibrated Zeiss Axiovision 4.8 digital camera system. Sections
from the central cornea were measured in six regions (2
peripheral, 2 intermediate and 2 central), mean thicknesses were
calculated for peripheral, intermediate and central corneal
epithelium. Cell layers were also counted for peripheral, interme-
diate and central regions in the same sections.
Immunohistochemical staining
Sections were de-waxed in histoclear and re-hydrated through a
graded alcohol series to water, incubated in 3% hydrogen
peroxide in methanol for 20 minutes rehydrated in 70% ethanol
and washed in phosphate buffered saline (PBS). Antigen unmask-
ing was performed by incubating slides in 0.01 M citrate buffer
Figure 1. Genetic background of mice used at different stages of the study. (A) Adult mice from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+)
crosses in stage 1. (B) Adult mice from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+) crosses used for wound healing experiment in stage 2. (C) Fetal and
juvenile mice from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+) crosses in stage 3. (D) Adult mice from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+) crosses in
stage 3. (E) Adult reporter mice from (Le-CreTg/26Z/AP) crosses in stage 3. (F) Adult mice from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+) crosses in
stage 4. (G) Adult mice from (Le-CreTg/2; Pax6fl/+6 PAX77Tg/2) crosses. See Table S1 and Materials and Methods for further details.
doi:10.1371/journal.pone.0109193.g001
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(pH 6.0) in a water bath heated to 95uC for 35 minutes; slides
were then allowed to cool for 20 min. and washed in PBS. Sections
were treated with 10% blocking serum (species according to
secondary antibody), 0.1% bovine serum albumin (BSA) in PBS
for 1 hour at room temperature. Sections were incubated
overnight at 4uC in the appropriate primary antibody, diluted in
blocking serum, as follows. (The following primary antibodies were
used. Pax6 staining: Developmental Studies Hybridoma Bank,
University of Iowa diluted 1:500. Cytokeratin 12 (K12): Santa
Cruz Biotechnology sc-17101 diluted 1:500. Cytokeratin 5 (K5):
Abcam ab53121 diluted 1:100. Cytokeratin 19 (K19): Lifespan
Biosciences LS-C3372 diluted 1:200). Slides were washed in PBS
and incubated in blocking serum for 10 min. then incubated with
secondary antibody, diluted in blocking serum, for 45 min. at
room temperature. (The following secondary antibodies were
used. Pax6 staining: Vector labs BA-9200 biotinylated goat anti-
mouse diluted 1:200. K12: Vector Labs BA-5000, biotinylated
rabbit anti-goat IgG diluted 1:200. K5 and K19: Vector Labs BA-
1000, biotinylated goat anti-rabbit IgG diluted 1:200). Slides were
washed in PBS and incubated with avidin-biotin reagent (ABC
RTU Vectastain, Vector Labs PK-7100). Antibody was then
visualised by 3,39-diaminobenzidine (DAB) stain (5.9 ml 20 mM
Tris pH 7.6, 100 ml 50 mg/ml DAB, 1 ml H2O2) and slides were
lightly counterstained with haematoxylin, dehydrated and cover-
slips were mounted with DPX mounting medium. Control slides
were treated with blocking serum in place of primary antibody but
otherwise treated identically.
b-galactosidase and alkaline phosphatase histochemical
staining on frozen sections
To prepare frozen tissue sections, samples were fixed in 4% PFA
overnight, washed three times for 15 minutes in PBS and
cryoprotected by treating with 15% sucrose in PBS for 1 hour at
4uC and then 30% sucrose overnight at 4uC. Tissues were
incubated in optimal cutting temperature compound (OCT) at
4uC for 1 hour before they were embedded in OCT over dry ice.
Blocks were stored at 280uC and warmed to 220uC before
cryosections were cut at 10 mm, air dried for at least 1 hour and
stored at 220uC.
Prior to staining, sections were fixed again with 0.2%
gluteraldehyde in ice cold PBS for 10 min. For b-galactosidase
(b-gal) staining, slides were washed three times for 5 min. in b-gal
wash buffer (2 mM, 0.01% sodium deoxycholate, 0.02% Nonidet-
P40 (NP-40) in 100 mM sodium phosphate, pH 7.3) and then
incubated in b-gal stain (0.5 mg/ml X-gal, 5 mM potassium
ferrocyanide, 5 mM potassium ferricyanide in b-gal wash buffer)
for 4–6 h. at 37uC, while protected from light. Slides were rinsed
in PBS, dehydrated through graded ethanols and coverslips were
mounted with DPX mounting medium. For alkaline phosphatase
(AP) staining, following fixation in 0.2% gluteraldehyde, slides
were washed three times for 5 min. in PBS. Endogenous
phosphatase activity was inactivated by incubating slides in PBS
at 70–75uC for 30 min., slides were rinsed in PBS and washed in
AP buffer (100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 10 mM
MgCl2) 10 min. Slides were incubated with nitro-blue tetrazolium
and 5-bromo-4-chloro-39-indolyphosphate (NBT/BCIP) stain for
10–30 min. at room temperature until the colour developed,
washed in PBS, dehydrated and coverslips were mounted with
DPX mounting medium.
Corneal epithelial wound healing
Mice were killed and a wound was made in the central region of
the cornea using a 1 mm diameter trephine blade, under a
dissecting microscope while the eye was in situ. The area within
the wound was debrided with an ophthalmological scalpel and the
wound was visualized with fluorescein dye and photographed
using a digital camera mounted on a dissecting microscope. Eyes
were enucleated and placed in culture wells (cornea facing up) in
corneal culture medium (CCM) [37] and kept in standard culture
conditions for 24 h. The wound area was visualised and
photographed at specific time points during culture and the
wound diameter was measured using Adobe Photoshop CS v8.
Statistical analysis
Left and right eyes were analysed separately because their
genotypes are identical so they are not completely independent
samples. Non-parametric Kruskal-Wallis tests and Dunn’s multiple
comparison post-hoc tests were performed using the statistics
package GraphPad Prism 5.0c (GraphPad Software Inc., San
Diego, USA). Fisher’s Exact tests were calculated using an on-line
statistics calculator (http://vassarstats.net/odds262.html). The
raw data are included in Supplementary Data S1.
Results
Morphology of Le-CreTg/-; Pax6fl/+ eyes from stage-1
crosses
Eyes from the experimental and three control genotypes
produced by Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+ crosses
were compared in four discrete stages as the genetic background
changed, as explained in the Materials and Methods section. The
average genetic background of the stage-1 progeny was approx-
imately 78% CBA/Ca, 5% FVB/N and 17% CD1 (Fig. 1A) and
results for this stage are summarised in Figs. 2–6 and Table 1.
(The four genotypes are colour-coded in each figure to help
distinguish them).
Haematoxylin and eosin staining of histological sections (one eye
per mouse) showed that control eyes (Le-Cre2/2; Pax6+/+, Le-Cre2/2;
Pax6fl/+ and Le-CreTg/2; Pax6+/+) were morphologically normal
(Figs. 2A–C), apart from two of the six Le-CreTg/2; Pax6+/+ eyes
examined, in which the irido-corneal angle appeared at least partly
closed due to adhesion between the iris and peripheral cornea
(Fig. 2D). All eight experimental Le-CreTg/2; Pax6fl/+ eyes examined
were morphologically abnormal but they varied in severity
(Figs. 2E,F). Lenses were small, malformed, vacuolated and not
always entirely contained within a capsule. Lens-corneal plugs
(persistent lens stalks) were present in some cases (Fig. 5M), as
described previously for both Pax6+/2 [26,38] and Le-CreTg/2;
Pax6fl/+ [28] mice. Retinal dysgenesis occurred in all Le-CreTg/2;
Pax6fl/+ samples examined and varied from mild folding or swirling
to more severe abnormalities. In most cases, there was no pupil and
pigmented tissue adhered to the corneal endothelium, which may
have been a persistent, pigmented pupillary membrane, as reported
for Pax6Leca4/+ heterozygotes [39]. There were also irido-lenticular
and irido-corneal adhesions and in some cases the irido-corneal angle
appeared closed and the ciliary body appeared abnormal or
hypoplastic (Fig. 2E). For frequency comparisons, eye morphology
was classified as normal, mildly abnormal or severely abnormal
(Table 1). For these stage-1 crosses, the frequency of eyes with
severely abnormal eyes was significantly greater than in the pooled
group of Le-Cre+/+; Pax6+/+ and Le-Cre+/+; Pax6fl/+ controls without
the Le-Cre transgene (0/12) by Fisher’s Exact test for Le-CreTg/2;
Pax6fl/+ eyes (6/8; P=0.0007) but not for Le-CreTg/2; Pax6+/+ eyes
(0/6; P=1.0000).
In stage 1, Le-CreTg/2; Pax6fl/+ eye size varied and some were
significantly smaller than the three control genotypes, which were
all similar, as shown for eye mass in Figs. 3A,D,G. For some Le-
CreTg/2; Pax6fl/+ mice, the mass of left and right eyes differed
Eye Abnormalities in Le-Cre Mice
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markedly, implying that both genetic and stochastic differences
can affect eye size. Comparisons of eye diameter and corneal
diameter measurements (Figs. S1 and S2) showed the same trends
as eye mass.
Abnormalities and immunohistochemistry of Le-CreTg/2;
Pax6fl/+ corneas (stage-1 crosses)
The original focus of this study was the corneal epithelium,
which was thinner in the experimental Le-CreTg/2; Pax6fl/+ group
than the three control groups at stage-1 (Figs. 4A–D) and this is
shown quantitatively in Fig. 6. As reported for Pax6+/Sey-Neu
heterozygotes [19], ectopic goblet cells were identified by PAS
staining in the corneal epithelium of two of the six Le-CreTg/2;
Pax6fl/+ eyes examined (Fig. 4L) but none were seen in 18 control
eyes (six for each genotype; Figs. 4I–K). The corneal epithelium of
all four genotypes stained positively for Pax6 (Figs. 4E–H) and
keratin 5 (K5; Figs. 5A–H). Staining of keratin 19 (K19), which is
normally expressed in the mouse conjunctiva and limbus but not
in the central cornea [40], was detected in conjunctival-limbal
region of all four groups (Figs. 5N–Q). As expected, it was absent
from the central cornea of the three control groups (Figs. 5I–K)
but patchy staining occurred in the central corneal epithelium of
the experimental Le-CreTg/2; Pax6fl/+ mice (Figs. 5L,M), as
reported previously for Pax6+/Sey-Neu heterozygotes [41], suggest-
ing that the corneo-limbal boundary may be indistinct. The
presence of K19 staining and goblet cells in the central corneal
epithelium is consistent with either conjuctivalisation or abnormal
differentiation of the Le-CreTg/2; Pax6fl/+ corneal epithelium. As
expected, keratin 12 (K12) immunostaining was detected through-
out the corneal epithelium of all three controls but, unexpectedly,
was completely absent from the corneal epithelium of all six Le-
CreTg/2; Pax6fl/+ eyes examined (Figs. 5R–Y). This is a signifi-
cantly more severe phenotype than reported for Pax6+/Sey-Neu
heterozygotes [19] [22]. Moreover, the presence of abnormalities
(closure of irido-corneal angles) in some Le-CreTg/2; Pax6+/+
control eyes suggested that depletion of Pax6 in the surface
Figure 2. Histology of adult eyes of four genotypes from Le-CreTg/2; Pax6+/+ 6 Le-Cre2/2; Pax6fl/+ crosses in stage 1. H & E stained
sections showing (A–C) normal morphology of (A) Le-Cre2/2; Pax6+/+, (B) Le-Cre2/2; Pax6fl/+ and (C) Le-CreTg/2; Pax6+/+ control eyes. (D) Another Le-
CreTg/2; Pax6+/+ eye with a closed irido-corneal angle (arrow) on the left of the photograph but an open angle to the right. (E,F) Experimental Le-
CreTg/2; Pax6fl/+eyes showing typical abnormalities. Scale bar = 200 mm. Abbreviations: cb, ciliary body; co, cornea; ir, iris; le, lens; re, retina. WT +/+ is
Le-Cre2/2; Pax6+/+; WT fl/+ is Le-Cre2/2; Pax6fl/+; Cre +/+ is Le-CreTg/2; Pax6+/+ and Cre fl/+ is Le-CreTg/2; Pax6fl/+. In each figure, the panel letters are
colour coded to help distinguish the genotypes.
doi:10.1371/journal.pone.0109193.g002
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Figure 3. Variation in eye mass for different genotypes at different stages of the study. (A–F) Mass of left (A–C) and right (D–F) eyes of 12-
week old mice from Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+ crosses on different genetic backgrounds: (A,D) stage 1 crosses (B,E) stage 3 crosses (C,F)
stage 4 crosses. (G–I) The percentage eye mass difference, calculated for each mouse as (larger eye mass - smaller eye mass)6100/(larger eye mass).
Eye Abnormalities in Le-Cre Mice
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ectoderm, by loxP recombination, might not be the sole cause of
eye abnormalities in the experimental Le-CreTg/2; Pax6fl/+ mice.
Corneal wound healing in Le-CreTg/2; Pax6fl/+ eyes
(stage-2 crosses)
Ex-vivo corneal epithelial wound healing, in the four groups,
produced by Le-CreTg/2; Pax6+/+6 Le-Cre2/2; Pax6fl/+ crosses,
was compared to wound healing in CBA/Ca- Pax6+/Sey-Neu
heterozygotes (Fig. S3). The Le-CreTg/-; Pax6+/+and Le-Cre2/2;
Pax6fl/+ mice had been crossed to CBA/Ca for more generations
and the genetic background had increased from approximately
78% CBA/Ca to approximately 93% CBA/Ca (Figs. 1A,B) so this
was considered to be a new stage of the study (stage 2). The
trajectory of wound healing was quite variable within groups and
some CBA/Ca- Pax6+/Sey-Neu wounds increased in size during the
first 6 hours, suggesting greater corneal epithelial fragility.
Comparisons of the frequencies of wounds that healed within
24 hours are shown both separately for left and right eyes and for
pooled samples of left and right eyes in Table S2. In each case
there is a trend for fewer wounds to close in CBA/Ca- Pax6+/Sey-
Neu positive controls and Le-CreTg/2; Pax6fl/+ experimental mice
than in Le-Cre2/2; Pax6+/+, Le-Cre2/2; Pax6fl/+ or Le-CreTg/2;
Pax6+/+ control groups but most differences failed to reach
significance by Fisher’s Exact tests unless results for left and right
eyes were pooled. Wound healing abnormalities in Pax6+/Sey-Neu
mice have been attributed to reduced Pax6 levels [23,24]. As
wound-healing was similar in Pax6+/Sey-Neu and Le-CreTg/2;
Pax6fl/+ mice, the wound-healing abnormalities in Pax6+/Sey-Neu
mice are likely to be at least partly mediated intrinsically via the
surface ectoderm lineage.
Morphology of experimental Le-CreTg/2; Pax6fl/+ eyes is
abnormal by E16.5 (stage 3 crosses)
We next compared eye morphology (one eye per mouse) in a
developmental series of H & E stained sections of fetal and juvenile
control Le-Cre2/2; Pax6+/+ and experimental Le-CreTg/2; Pax6fl/+
eyes (Fig. 7) to identify when the abnormalities seen in adult Le-
CreTg/2; Pax6fl/+ experimental mice (Fig. 2) arose. By this stage,
Le-CreTg/2; Pax6+/+and Le-Cre2/2; Pax6fl/+ mice had been
crossed to CBA/Ca for more generations and the genetic
background had increased from approximately 93% to approx-
imately 98% CBA/Ca (Figs. 1B,C) so this was considered to be
Abbreviations: WT +/+ is Le-Cre2/2; Pax6+/+; WT fl/+ is Le-Cre2/2; Pax6fl/+; Cre +/+ is Le-CreTg/2; Pax6+/+ and Cre fl/+ is Le-CreTg/2; Pax6fl/+. Results for all
four genotypes were compared by non-parametric Kruskal-Wallis (KW) tests separately for each stage of the study (P-values are shown in the figure)
and results for WT fl/+, Cre +/+ and Cre fl/+ were compared to WT +/+ by Dunn’s multiple comparison post-hoc test: *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0109193.g003
Figure 4. Histology and immunohistochemistry of adult corneas of four genotypes from Le-CreTg/2; Pax6+/+ 6 Le-Cre2/2; Pax6fl/+
crosses in stage 1. (A–D) H & E stained corneas showing normal morphology in controls (A–C) but reduced numbers of corneal epithelial layers in
the Le-CreTg/2; Pax6fl/+ cornea shown in (D). (E–H) Pax6 immunostaining (brown endpoint) in the corneal epithelium of all four genotypes. (I–L)
Periodic acid-Schiff (PAS) staining (purple-magenta endpoint) in cornea showed goblet cells were absent from the corneal epithelium of the three
control genotypes (I–K) and some experimental Le-CreTg/2; Pax6fl/+ eyes (not shown) but present in other Le-CreTg/2; Pax6fl/+ eyes (arrows in L). Scale
bars: A–H= 20 mm, I–L = 50 mm. Abbreviations: en, corneal endothelium; ep, corneal epithelium; st, corneal stroma.
doi:10.1371/journal.pone.0109193.g004
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Figure 5. Immunohistochemistry for keratins 5, 19 and 12 in epithelia of the adult ocular surface of four genotypes from Le-CreTg/2;
Pax6+/+6Le-Cre2/2; Pax6fl/+ crosses in stage 1. (A–H) Keratin 5 (K5) immunostaining (brown endpoint) shows K5 is present in the central (A-D)
and peripheral (E–H) corneal epithelium of all four groups. (I–Q) K19 immunostaining (brown endpoint) in the central corneal epithelium (I–M) shows
K19 is absent in the three control groups (I–K) but patchy staining (arrows) is present in the Le-Cre2/2; Pax6fl/+ central corneal epithelium (L,M). The
cornea shown in M has a lens-corneal plug. In the peripheral corneal epithelium (N–Q), K19 is present in some cells of the limbus (and conjunctiva) in
all four groups. (R–X) K12 immunostaining (brown endpoint) in the central corneal epithelium (R–U) and peripheral corneal and limbal epithelium (V–
Y) shows K12 is absent from the Le-CreTg/2; Pax6fl/+ ocular surface epithelium (U,Y) but present in the corneal epithelium of all three control groups
(R–T and V–X). Scale bars = 50 mm. Abbreviations: co, cornea; cj, conjunctiva; lcp, lens-corneal plug; li, limbus.
doi:10.1371/journal.pone.0109193.g005
Eye Abnormalities in Le-Cre Mice
PLOS ONE | www.plosone.org 8 October 2014 | Volume 9 | Issue 10 | e109193
stage 3. Abnormalities were first detected as disorganised lenses in
E16.5 Le-CreTg/2; Pax6fl/+ eyes (Fig. 7F) whereas Le-Cre2/2;
Pax6+/+ control eyes were normal (Fig. 7E). By P2 abnormalities
in Le-CreTg/2; Pax6fl/+ eyes were very obvious. Eyes and lenses
were smaller than in controls, the retina was dysplastic (retinal
swirls) and pigmented iris like-tissue adhered to the corneal
endothelium (Fig. 7H).
Eye morphology is abnormal in Le-CreTg/2; Pax6+/+
controls as well as Le-CreTg/2; Pax6fl/+ experimental mice
from stage-3 crosses
At P10 we also examined the other two control groups (Le-
Cre2/2; Pax6fl/+ and Le-CreTg/2; Pax6+/+). As expected, all five of
the experimental Le-CreTg/2; Pax6fl/+ eyes examined were
abnormal (Figs. 7M,N). More surprisingly, some P10 control Le-
CreTg/2; Pax6+/+ eyes from stage-3 crosses also displayed a much
more obvious abnormal phenotype than the partly closed irido-
corneal angles seen in stage 1 adults. Three of the five Le-CreTg/2;
Pax6+/+ control eyes examined appeared normal (Fig. 7K) but two
had abnormal lenses (Fig. 7L). In contrast, all the Le-Cre2/2;
Pax6+/+ and Le-Cre2/2; Pax6fl/+ controls examined (4 eyes per
genotype) appeared normal (Figs. 7I,J).
The eyes of the adult control Le-CreTg/2; Pax6+/+ mice from
stage-3 crosses, as well as the experimental Le-CreTg/2; Pax6fl/+
mice, varied in size and many were smaller than the Le-Cre2/2;
Pax6+/+ and Le-Cre2/2; Pax6fl/+ controls, as shown by the
quantitative comparisons of eye mass (Figs. 3B,E,H) plus compar-
isons of eye and corneal diameters (Figs. S1 and S2). Furthermore,
by this stage many of the Le-CreTg/2; Pax6+/+ stock mice,
produced by crossing Le-CreTg/2; Pax6+/+ to CBA/Ca (rather
than crossing them to Le-Cre2/2; Pax6fl/+ to produce mice for
analysis), also had overtly small eyes (data not shown). While adult
stage-3 Le-Cre2/2; Pax6+/+ and Le-Cre2/2; Pax6fl/+ controls
continued to display a normal wild-type histological phenotype
(Figs. 8A,B,E,F), four of the six Le-CreTg/2; Pax6+/+ control eyes
examined were morphologically abnormal (Fig. 8G) and the other
Figure 6. Variation in corneal epithelial thickness in different genotypes from stage-1 crosses. Variation in corneal thickness in 12-week-
old mice of different genotypes from Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+ stage 1 crosses. Variation in (A–C) number of corneal epithelial layers,
(D–F) corneal epithelial thickness (mm) at the periphery (A,D), intermediate (B,E) and central (C,F) cornea in 12 week old mice of different genotypes
from Le-CreTg/2; Pax6+/+6 Le-Cre2/2; Pax6fl/+ stage 1 crosses. Results are means of two measurements at the periphery, intermediate and central
regions of 4–6 eyes (1 eye per mouse) per genotype. Abbreviations: WT +/+ is Le-Cre2/2; Pax6+/+, WT fl/+ is Le-Cre2/2; Pax6fl/+, Cre +/+ is Le-CreTg/2;
Pax6+/+ and Cre fl/+ is Le-CreTg/2; Pax6fl/+. Results for all four genotypes were compared by non-parametric Kruskal-Wallis (KW) tests separately for
each corneal region (P-values are shown in the figure) and results for WT fl/+, Cre +/+ and Cre fl/+ were compared to WT +/+ by Dunn’s multiple
comparison post-hoc test: * P,0.05;** P,0.01.
doi:10.1371/journal.pone.0109193.g006
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two appeared normal (Fig. 8C). The types of abnormalities seen in
the stage-3 Le-CreTg/2; Pax6+/+ control mice was similar to those
reported for some heterozygous Pax6+/2 mice (e.g. small
disorganised lens, thinner corneal epithelium, irido-corneal
adhesions and irido-lenticular adhesions). The experimental Le-
CreTg/2; Pax6fl/+ eyes displayed a range of severe abnormalities
(Figs. 8D,H) that were similar to those seen in stage-1 experimen-
tal Le-CreTg/2; Pax6fl/+ eyes (Figs. 2E,F).
For stage-3 crosses, the frequency of eyes with severe abnormal-
ities was significantly greater than in the two control groups without
the Le-Cre transgene (0/12) by Fisher’s Exact test for both Le-CreTg/
2; Pax6fl/+ and Le-CreTg/2; Pax6+/+ eyes (3/6; P=0.0245 in both
cases) as shown in Table 1. Although the frequency of Le-CreTg/2;
Pax6+/+ eye abnormalities was higher at stage 3 than stage 1 this
difference did not reach statistical significance either for all
abnormalities (4/6 vs. 2/6; P=0.5671) or severe abnormalities
(3/6 vs. 0/6; P=0.1818). However, as noted above, eye abnor-
malities were significantly more frequent in Le-CreTg/2; Pax6+/+
than the two control groups without the Le-Cre transgene at stage 3
(4/6 vs. 0/12; P=0.0049 for all abnormalities and 3/6 vs. 0/12;
P=0.0245 for just the severe abnormalities) but not at stage 1 (2/6
vs. 0/12; P=0.0980 for all abnormalities and 0/6 vs. 0/12;
P=1.0000 for severe abnormalities). This comparison indicates
that the trend for more Le-CreTg/2; Pax6+/+ eye abnormalities at
stage 3 than stage 1 is significant.
Figure 7. Morphology of fetal and juvenile eyes and Z/AP reporter expression in adult eyes from mice produced in stage 3. (A–H)
Comparison of morphology in H & E stained histological sections of control Le-Cre2/2; Pax6+/+ and experimental Le-CreTg/2; Pax6fl/+ fetal and neonatal
eyes from (Le-CreTg/2; Pax6+/+6Le-Cre2/2; Pax6fl/+) stage-3 crosses at E12.5 to P2 showing lens abnormalities in Le-CreTg/2; Pax6fl/+ eyes at E16.5 (F)
and more extensive ocular abnormalities in Le-CreTg/2; Pax6fl/+ eyes at P2 (H). (I–N) Comparison of morphology in H & E stained histological sections
of all three control genotypes from (Le-CreTg/2; Pax6+/+6 Le-Cre2/2; Pax6fl/+) stage-3 crosses at P10 showing normal morphology of (I) Le-Cre2/2;
Pax6+/+, (J) Le-Cre2/2; Pax6fl/+ and (K) one Le-CreTg/2; Pax6+/+ controls but abnormal morphology in (L) another Le-CreTg/2; Pax6+/+ control and (M,N)
eyes from Le-CreTg/2; Pax6fl/+ experimental mice in stage 3 of this study. The lenses in I-K are normal but the lens shown in (J) was damaged during
sectioning. (O,P) Histochemical staining for (O) placental alkaline phosphatase (blue endpoint) and (P) b-galactosidase (blue endpoint) in different
sections from the same Le-CreTg/2; Z/AP adult reporter eye showing AP staining is restricted to the surface ectoderm derivatives (lens and corneal
epithelium). Eye morphology in the Le-CreTg/2; Z/AP eyes was often abnormal in stage 3 (O,P), as it was for some Le-CreTg/2; Pax6+/+ controls in stage 3
(L and Fig. 8). Scale bars: E12.5 and E14.5 (A–D) = 50 mm; E16.5 and P2 (E–H) = 200 mm, P10 (I–N) = 100 mm; 12 weeks (O,P) = 200 mm. Abbreviations:
AP, alkaline phosphatase staining; b-gal = b-galactosidase staining. Colour code of panel lettering: black = Le-Cre2/2; Pax6+/+; blue = Le-Cre2/2;
Pax6fl/+; red = Le-CreTg/2; Pax6+/+; green = Le-CreTg/2; Pax6fl/+; purple = Le-CreTg/2; Z/AP.
doi:10.1371/journal.pone.0109193.g007
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As in the stage-1 cross, Pax6 immunostaining occurred in the
corneal epithelium of all four genotypes from the stage-3 crosses
(Figs. 8I–L). K12 immunostaining was examined in six eyes from
each of the four genotypes. K12 was detected throughout the
corneal epithelium of all three controls (Figs. 8M–O), including
the four Le-CreTg/2; Pax6+/+ eyes that were morphologically
Figure 8. Morphology of eyes and corneal immunostaining for Pax6 and K12 from adults in stage 3. (A–H) H & E stained sections of
adult eyes from stage-3 crosses (with a predominantly CBA/Ca genetic background) showing normal morphology of (A,E) Le-Cre2/2; Pax6+/+, (B,F) Le-
Cre2/2; Pax6fl/+ and (C) an Le-CreTg/2; Pax6+/+ control eye but abnormal morphology of (G) another Le-CreTg/2; Pax6+/+ control eye and a range of
morphological abnormalities in (D,H) experimental Le-CreTg/2; Pax6fl/+eyes. (I–L) Pax6 immunostaining (brown endpoint) in the corneal epithelium of
all four genotypes. (M–P) K12 immunostaining (brown endpoint) in the central corneal epithelium shows K12 is present in the corneal epithelium of
all three control eyes but absent from the Le-CreTg/2; Pax6fl/+ corneal epithelium. (Q–S) Low power views of K12 immunostaining (brown endpoint)
across the whole corneal epithelium showing (Q) strong staining in an Le-Cre2/2; Pax6+/+control eye, (R) no staining in an Le-CreTg/2; Pax6fl/+ eye and
(S) weak and patchy staining in a heterozygous Pax6+/Sey-Neu eye (arrow shows a K12-positive region). (T) Higher power view of a K12-positive region
in the corneal epithelium of an adult Pax6+/Sey-Neu heterozygote. Scale bars: A–P (shown in the first panel of each row) and T= 200 mm, Q–S (shown in
Q) = 500 mm.
doi:10.1371/journal.pone.0109193.g008
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abnormal, but it was again undetectable in the corneal epithelium
of all the experimental Le-CreTg/2; Pax6fl/+ eyes examined
(Fig. 8P). Figs. 8S,T show weak and patchy K12 immunostaining
in the corneal epithelium of an adult Pax6+/Sey-Neu mouse (17-
weeks old) that was congenic on a CBA/Ca genetic background
(.20 generations of backcrosses). This differs from both the strong
staining in Le-Cre2/2; Pax6+/+ controls (Figs. 8M,Q) and the
undetectable staining of Le-CreTg/2; Pax6fl/+ eyes (Figs. 8P,R)
from stage-3 crosses, with a similar genetic background.
To check whether the Le-Cre transgene was being ectopically
expressed we stained separate sections of eyes from Le-CreTg/2; Z/
AP reporter mice for alkaline phosphatase and b-galactosidase
expression. These mice had a similar genetic background to other
stage 3 mice (estimated as approximately 97% CBA/Ca, 0.3%
FVB/N and 2.3% CD1; Fig. 1E). The Z/AP reporter mouse uses
a double reporter system to provide an assay for Cre-mediated
recombination of loxP sites. Before recombination, cells express
lacZ but upon recombination the lacZ reporter is excised and lacZ
expression is replaced with alkaline phosphatase (AP) expression
[36]. Alkaline phosphatase was expressed in the corneal epithe-
lium and lens of Le-CreTg/2; Z/AP eyes (Fig. 7O), confirming that
Cre-recombinase was expressed appropriately. These stage-3 Le-
CreTg/2; Z/AP eyes had abnormal lenses and AP-positive cells
were not all contained within a lens capsule. b-galactosidase
staining on sections of the same eyes revealed lacZ expression in
the retina where, as expected, no Cre-mediated excision had
occurred (Fig. 7P). Thus, despite the morphological abnormalities
there was no evidence for ectopic Le-Cre expression in these stage-
3, Le-CreTg/2; Z/AP reporter mice.
Eye morphology in Le-CreTg/2; Pax6+/+ control eyes is
improved by changing the genetic background (stage-4
crosses)
Comparisons of eye morphology in mice from crosses in stages 1
and 3 suggested that continued backcrossing to CBA/Ca was
associated with a marked increase in abnormalities in control Le-
CreTg/2; Pax6+/+ eyes. In stage 4 of this study we, therefore,
investigated whether increasing the contribution of the FVB/N
genetic background, which was originally used to maintain the Le-
Cre transgene, would reduce the level of abnormalities. Le-CreTg/
2; Pax6+/+ mice that had been backcrossed to CBA/Ca for 8
generations (99.6% CBA and 0.4% FVB) were backcrossed to
FVB for a further two generations and then crossed to Le-Cre2/2;
Pax6fl/+ mice that had been backcrossed to CBA/Ca for 5 or 6
generations to produce four genotypes with genetic backgrounds
estimated as 61% CBA, 38% FVB and 1% CD1 (Fig. 1F). This
resulted in a significant improvement in morphology of control Le-
CreTg/2; Pax6+/+ eyes, although experimental Le-CreTg/2; Pax6fl/+
eyes remained severely abnormal (Figs. 9A–F). A mildly abnormal
phenotype (mild lens abnormalities and slight retinal swirling) was
detected in 2 of the 6 Le-CreTg/2; Pax6+/+ control eyes examined
(Fig. 9D) but the other 4 eyes were normal (Fig. 9C).
For stage-4 crosses, the frequency of eyes with severely
abnormal eyes was significantly greater than in the two control
groups without the Le-Cre transgene (0/8) by Fisher’s Exact test
for Le-CreTg/2; Pax6fl/+ eyes (4/6; P=0.0150) but not for Le-
CreTg/2; Pax6+/+ eyes (0/6; P=1.0000) as shown in Table 1.
Although the frequency of Le-CreTg/2; Pax6+/+ eye abnormalities
was lower at stage 4 than stage 3 this difference was not significant
either for all abnormalities (2/6 vs. 4/6; P=0.5671) or severe
abnormalities (0/6 vs. 3/6; P=0.1818). However, the trend for
fewer Le-CreTg/2; Pax6+/+ eye abnormalities at stage 4 is
supported by comparisons between Le-CreTg/2; Pax6+/+ eyes
and the two control groups without the Le-Cre transgene at stages
3 and 4. The frequency was significantly higher among Le-CreTg/
2; Pax6+/+ eyes at stage 3 (4/6 vs. 0/12; P=0.0049 for all
abnormalities and 3/6 vs. 0/12; P=0.0245 for severe abnormal-
ities) but not at stage 4 (2/6 vs. 0/8; P=0.1648 for all
abnormalities and 0/6 vs. 0/8; P=1.000 for severe abnormalities).
The improved morphology of the control Le-CreTg/2; Pax6+/+
eyes, in stage-4 crosses, was accompanied by a more normal and
less variable eye size, as demonstrated by measurements of eye
mass (Figs. 3C,F,I), eye diameter (Fig. S1) and corneal diameter
(Fig. S2). Experimental Le-CreTg/2; Pax6fl/+ eyes from this stage-4,
FVB cross remained small but were less variable in size than those
from stage 1 and stage 3 crosses (Fig. 3, Figs. S1 and S2). Pax6 and
K12 immunostaining results (data not shown) were unchanged
from results shown Figs. 4, 5 and 8 for stages 1 and 3.
Increased Pax6 expression provides a partial rescue of
Le-CreTg/2; Pax6fl/+ and Le-CreTg/2; Pax6+/+ abnormal eye
phenotypes on a predominantly CBA/Ca genetic
background
To determine whether increased Pax6 levels could rescue the
eye abnormalities seen in Le-CreTg/2; Pax6+/+ controls from stage-
3 crosses, we crossed Le-CreTg/2; Pax6fl/+ mice with approxi-
mately 98% CBA/Ca genetic background to CBA/Ca-PAX77Tg/
2 mice (on an almost 100% CBA/Ca genetic background). This
transgene contains the human PAX6 gene so over-expresses Pax6
[33] and affects the eye and corneal phenotypes [42] [34]. The
genetic background of the progeny was approximately 99% CBA/
Ca, 0.2% FVB and 0.8% CD1 (Fig. 1G). Comparisons of eye
phenotypes of control Le-CreTg/2; Pax6+/+; PAX772/2 (without
the PAX77 transgene) and Le-CreTg/2; Pax6+/+; PAX77Tg/2 eyes
(with the PAX77 transgene) and comparisons of experimental Le-
CreTg/2; Pax6fl/+; PAX772/2 and Le-CreTg/2; Pax6fl/+;
PAX77Tg/2 eyes are shown in Figs. 9G–J. As expected, the
abnormal phenotypes of the experimental Le-CreTg/2; Pax6fl/+
eyes (with reduced Pax6 levels in the surface ectoderm) was
partially rescued by the presence of the PAX77 transgene (which
provides additional Pax6) as shown in Figs. 9G,H.
Although the frequency of severely abnormal eyes was lower for
Le-CreTg/2; Pax6fl/+; PAX77Tg/2 mice with the PAX77 transgene
(0/3) than for Le-CreTg/2; Pax6fl/+; PAX772/2 mice without
PAX77 (3/3) these differences did not reach significance by a 2-
tailed Fisher’s Exact test (P=0.1000; Table 1) but were bordering
on significance by a 1-tailed test (P=0.05). Interestingly, the
abnormal phenotypes of the control Le-CreTg/2; Pax6+/+ eyes
were also partially rescued by the presence of the PAX77
transgene even though the genetic background was quite similar
to that of the stage 3 crosses (Figs. 9I,J). Thus, the frequency of
severely abnormal eyes was lower for Le-CreTg/2; Pax6+/+;
PAX77Tg/2 mice with the PAX77 transgene (0/3) than for Le-
CreTg/2; Pax6+/+; PAX772/2 mice without PAX77 (2/3) but
again the small sample size lacked statistical power and these
differences did not reach significance by Fisher’s Exact test
(P=0.4000; Table 1).
In both Le-CreTg/2; Pax6+/+; PAX77Tg/2 and Le-CreTg/2;
Pax6fl/+; PAX77Tg/2 genotypes, the most noticeable improvement
in the phenotype attributable to the presence of the PAX77
transgene was normalisation of lens size and morphology and
absence of retinal dysgenesis (swirling and folding), although irido-
corneal adhesions remained and the retina appeared thinner than
normal. The retinal hypoplasia might reflect elevated Pax6 levels
in the neuroectoderm lineage because the PAX77 transgene will
produce a global increase in Pax6 but this will only be balanced by
Pax6 depletion, caused by the Le-CreTg/2; Pax6fl/+ genotype, in
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the surface ectoderm derivatives. Even if Pax6 levels are more
normal in the surface ectoderm lineage they are likely to be
abnormally high in the tissues derived from the neuroectoderm of
the optic cup. The striking partial rescue of control Le-CreTg/2;
Pax6+/+ eye phenotypes by the PAX77 transgene on a predom-
inantly CBA/Ca genetic background suggests that low Pax6 levels
may mediate the abnormal phenotype of control Le-CreTg/2;
Pax6+/+ eyes as well as the experimental Le-CreTg/2; Pax6fl/+ eyes.
Discussion
Eye abnormalities in Le-CreTg/2; Pax6fl/+ experimental
mice from stage-1 crosses
Pax6 was expected to be reduced to heterozygous levels in only
the surface ectoderm derivatives of Le-CreTg/2; Pax6fl/+ mice, so it
was predicted that the range of abnormalities would be either
similar to those reported for Pax6+/2 heterozygotes (if all their eye
abnormalities were mediated via the surface ectoderm derivatives)
or less extensive than those reported for Pax6+/2 (if some Pax6+/2
eye abnormalities were mediated via depletion of Pax6 in other
lineages). Unexpectedly, the experimental Le-CreTg/2; Pax6fl/+
mice appeared more abnormal, in some respects, than the eye
phenotypes reported for global depletion of Pax6 in heterozygous
Pax6+/Sey-Neu (Pax6+/2) mice [19,22], as shown in Table 2. For
example, K12 staining was undetectable in the Le-CreTg/2; Pax6fl/
+ corneal epithelium.
This striking and unexpected result was seen both at stage 1
(,78.1% CBA/Ca) and stage 3 (,98.1% CBA/Ca). As far as we
are aware, this has not been reported previously for any
heterozygous Pax6+/2 mice, regardless of the Pax62 null allele
involved. It is a significantly more severe phenotype than reported
for Pax6+/Sey-Neu heterozygotes, which showed patchy, weak to
strong K12 staining at a similar age on a genetic background
comprising 75% CBA/Ca and 25% C57BL [22]. K12 staining
was also detectable in corneal epithelia of adult Pax6+/Sey-Neu
heterozygotes that were congenic on a CBA/Ca genetic
background (Figs. 8S,T). K12 is a marker for corneal-type
epithelial differentiation [43] and is regulated by Pax6
[44,45,46]. The absence of K12 indicates that corneal epithelial
differentiation is abnormal and implies that experimental
Figure 9. Partial rescue of adult eye abnormalities by changing the genetic background or increasing Pax6 levels. (A–F) H & E stained
sections of adult eyes from stage 4 crosses (crossed to CBA/Ca for 8 generations and then FVB/N for 2 generations) showing normal morphology of
(A) Le-Cre2/2; Pax6+/+ and (B) Le-Cre2/2; Pax6fl/+ control eyes and relatively few abnormalities in (C,D) Le-CreTg/2; Pax6+/+ control eyes but more severe
abnormalities in (E,F) experimental Le-CreTg/2; Pax6fl/+eyes. (G–J) H & E stained sections of adult eyes from crosses between stage-3 Le-CreTg/2; Pax6fl/+
mice and CBA-PAX77Tg/2 transgenic mice (with elevated Pax6 levels, congenic on a CBA/Ca genetic background). (G,H) The effect of additional Pax6
from the PAX77 transgene on Le-CreTg/2; Pax6+/+ control genotype is shown by comparing the morphology of (G) the Le-CreTg/2; Pax6+/+; PAX772/2
control eye (without the PAX77 transgene) and (H) the Le-CreTg/2; Pax6+/+; PAX77Tg/2 eye (with the PAX77 transgene). (I,J) The effect of additional Pax6
from the PAX77 transgene on Le-CreTg/2; Pax6fl/+ experimental genotype is shown by comparing the morphology of (I) the Le-CreTg/2; Pax6fl/+;
PAX772/2 control eye (without the PAX77 transgene) and (J) the Le-CreTg/2; Pax6fl/+; PAX77Tg/2 eye (with the PAX77 transgene). The lenses in A–C, H &
J were normal but some were damaged during sectioning. Scale bars A–J = 200 mm. Abbreviations: Cre +/+77 is Le-CreTg/2; Pax6+/+; PAX77Tg/; and Cre
fl/+77 is Le-CreTg/2; Pax6fl/+; PAX77Tg/2. Colour code of panel lettering: black = Le-Cre2/2; Pax6+/+; blue = Le-Cre2/2; Pax6fl/+; red = Le-CreTg/2; Pax6+/+
or Le-CreTg/2; Pax6+/+; PAX77Tg/2; green = Le-CreTg/2; Pax6fl/+ or Le-CreTg/2; Pax6fl/+; PAX77Tg/2.
doi:10.1371/journal.pone.0109193.g009
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Le-CreTg/2; Pax6fl/+ corneas are more severely affected than
Pax6+/Sey-Neu heterozygotes.
Some stage-1 Le-CreTg/2; Pax6fl/+ abnormalities appear more
similar to those described for Pax6Leca4/+ heterozygotes [39] or
Pax6Sey/+ heterozygotes on an outbred CD1 background [47]
(Table 2), although K12 immunohistochemistry was not evaluated
in either of these studies. Even during the first stage of our study,
some Le-CreTg/2; Pax6+/+ controls appeared slightly abnormal, as
they had partly closed irido-corneal angles. Thus, the greater
abnormalities in Le-CreTg/2; Pax6fl/+ eyes compared to Pax6+/Sey-
Neu mice could be mediated by additional, unknown effects specific
to the Le-Cre transgene. Conversely, corneal neovascularisation
occurs in Pax6+/2 mice but was not seen in the Le-CreTg/2; Pax6fl/
+ experimental mice analysed, suggesting either that it is mediated
by lineages other than the surface ectoderm or the Le-CreTg/2;
Pax6fl/+ genetic background is less-permissive for this phenotype
than the genetic background used for the Pax6+/2 studies.
Eye abnormalities in Le-CreTg/2; Pax6+/+ control mice from
stage-3 crosses
After further backcrosses to CBA/Ca mice, eyes of Le-CreTg/2;
Pax6fl/+ experimental mice from stage 3 crosses were again
severely affected but now some Le-CreTg/2; Pax6+/+ controls also
had small and abnormal eyes. The types of abnormalities seen in
these Le-CreTg/2; Pax6+/+ control mice were similar to those
reported for some heterozygous Pax6+/2 mice. We attribute these
abnormalities to the presence of the Le-Cre transgene because no
Table 2. Comparison of eye phenotypes in control Le-CreTg/-; Pax6+/+, experimental Le-CreTg/-; Pax6fl/+ and different Pax6
heterozygous mice.
Genotype
Le-CreTg/-; Pax6+/+
(from stage 1 crosses)
Le-CreTg/-; Pax6fl/+
(from stage 1
crosses) Pax6+/Sey-Neu Pax6Sey/+ Pax6Leca4/+
Genetic background ,78% CBA, ,5% FVB
& ,17% CD1
,78% CBA, ,5%
FVB & ,17% CD1
75% CBA & 25%
C57BL* or 100%
CBA**
CD1 (outbred) mixed (unspecified)
Reference present study present study [19,22,41] [47] [39]
Phenotypes
1. Eye size (mass or diameter) normal (Fig. 3) some are small
(Fig. 3)
small small very small
2. Corneal epithelial layers normal (Figs. 4-6) reduced (Figs. 4-6) reduced reduced reduced
3. Keratin 12 immunostaining
in cornea
positive staining
(Figs. 5T,X)
absent (Figs. 5U,Y) reduced staining ND ND
4. Keratin 19 immunostaining
in
limbus not cornea limbus & patchy in
cornea
limbus & cornea** ND ND
cornea (Figs. 5K,P) (Figs. 5L,M,Q)
5. Goblet cells in corneal
epithelium
absent (Fig. 4K) present (Fig. 4L) present ND absent
6. Blood vessels in cornea none seen none seen present in some present present very early
7. Lens structure normal (Figs. 2C,D) cataracts and
abnormal (Figs. 2E,F)
cataracts cataracts cataracts and vacuolated.
8. Lens-corneal plug in
corneal epithelium
(persistent lens stalk)
absent (Figs. 2,4,5) lens-corneal plug
in some corneas
(Fig. 5M)
lens-corneal plug
present
lens-corneal plug
in some corneas
absent
9. Kerato-lenticular adhesions
or strands
absent absent some adhesions strands adhesions
10. Irido-corneal adhesions
(anterior synechia) or strands
mostly absent
(Figs. 2C,D) but
see point 11.
some adhesions
(Figs. 2E,F, 5) –
also see point 13
adhesions adhesions adhesions and strands
11. Irido-corneal angles mostly open angles
(Fig. 2C) but some
appear partly closed
(Figs. 2D, 5G,X)
Most eyes severely
abnormal and angles
closed (Figs. 2E,5)
closed angles closed angles closed angles
12. Irido-lenticular adhesions
(posterior synechia)
absent (Figs. 2C,D) some adhesions
present (Fig. 2F) –
also see point 13
absent adhesions present adhesions present
13. Iris normal (Figs. 2C,D) malformed iris &
pigmented pupillary
membrane (Figs. 2F, 5)
hypoplastic hypoplastic malformed iris & pigmented
pupillary membrane
14. Ciliary body normal (Figs. 2C,D) sometimes abnormal
or hypoplastic (Fig. 2E)
normal hypoplastic malformed
15. Retina normal (Figs. 2C,D) dysplastic (Figs. 2E,F) normal dysplastic dysplastic
*C57BL is derived from the UK C57BL/GrFa strain via C57BL/Ola and is closely related to the C57BL/6 strain [69].
**Genetic background for Pax6+/Sey-Neu K19 study was 100% CBA/Ca [41]. ND, not done.
doi:10.1371/journal.pone.0109193.t002
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abnormalities were seen in the Le-Cre2/2; Pax6fl/+ or Le-Cre2/2;
Pax6+/+ controls without the Le-Cre transgene. We also observed
some variability in eye mass between left and right eyes from the
same Le-CreTg/2; Pax6+/+ mice, indicating that stochastic
variability occurs as well as variability attributed to differences in
genetic background. Liu et al. [5] reported variation for lens
abnormalities in Le-Cre; Six3fl/2 mice, which they attributed to
variability in the timing and extent of Le-Cre activity on the
NMRI genetic background that was used. However, stochastic
variation in eye size has also been reported for mice with reduced
or elevated Pax6 levels, which is not controlled by Cre-
recombinase [34,39].
Reducing Le-Cre eye abnormalities by manipulating the
genetic background or Pax6 levels
When Le-CreTg/2; Pax6+/+ mice from generation 8 were crossed
to FVB/N for two generations before crossing them to Le-Cre2/2;
Pax6fl/+ mice (stage 4 experiments), the eye abnormalities in Le-
CreTg/2; Pax6+/+ control progeny were less frequent and much less
severe than in stage 3. This partial rescue of the eye phenotype
implies that a genetic background effect is involved and the
abnormal stage-3 Le-Cre2/2; Pax6fl/+ phenotype is not caused by
an inherited mutation. Together these results suggest that the eye
abnormalities are mediated by an interaction between the Le-
CreTg/2 transgene and alleles of unknown modifier genes present
in certain genetic backgrounds, including CBA/Ca. Finally,
introduction of the PAX77 transgene to the Le-CreTg/2; Pax6+/+
genotype also reduced the severity of the eye abnormalities
suggesting that increasing the Pax6 level could counteract the
effects of the Le-CreTg/2 transgene on a largely CBA/Ca genetic
background.
Abnormalities in other Cre-loxP experiments
A number of possible pitfalls with Cre-loxP experiments have
been identified and reviewed elsewhere [48,49,50]. These include
(i) unexpected Cre expression patterns in somatic tissues; (ii)
unexpected Cre expression in the germ line leading to deletion of
floxed genes in all cells of individuals in the next generation [51]
[52]; (iii) variation among floxed alleles in their sensitivity to Cre-
mediated recombination and (iv) toxic effects of Cre. The genetic
background may affect the pattern of loxP recombination [53] but
it is not known whether this acts by altering Cre-recombinase
expression (i) or another mechanism. Collectively, these problems
indicate that Cre-loxP experiments are not always as robust as is
often assumed. In our experiments, the abnormalities occurred in
Le-CreTg/2; Pax6+/+ but not Le-Cre2/2; Pax6fl/+ controls,
implicating the Le-Cre transgene rather than loxP.
One type of Cre toxicity involves the action of Cre recombinase
on cryptic pseudo-loxP sites, which are present in the endogenous
mouse genome [54,55] but, to have any detectable effect, this may
require prolonged expression of high levels of Cre recombinase
[56,57,58]. Such action may result in mutations and chromosomal
abnormalities, by introducing single-stranded and double-stranded
DNA breaks even if Cre-mediated recombination does not occur
[55,59]. This has been implicated as the cause of sterility in mice
expressing Cre recombinase in spermatids [60]. In somatic cells a
common phenotypic effect is likely to be reduced cell proliferation
and cell cycle arrest [57,61] leading to increased cell death. This
may be relatively well tolerated and it has been suggested that
many Cre-expressing transgenic strains that appear superficially
normal are not actually completely normal, as often the effects of
Cre cytotoxicity would be ameliorated by a combination of
developmental selection and adaptation [48]. Nevertheless,
abnormal phenotypes have been reported as a result of Cre
expression in somatic cells, including (i) brain damage (e.g.
reduced neuronal proliferation, increased aneuploidy and apop-
tosis, microencephaly and hydrocephaly) [61,62,63], (ii) damage to
the retinal pigment epithelium [64], (iii) glucose intolerance [65],
(iv) cardiomyopathy leading to heart failure [66] and (v)
tetraploidy among epidermal keratinocytes [59]. Activation of
CreERT2 transgenes with tamoxifen treatment has also been
associated with abnormalities in transgenic mice, including
reduced proliferation and increased apoptosis in haematopoietic
tissues [63,67]. There was no clear evidence of a genetic
background effect in these studies although this possibility was
considered for glucose intolerance, which was observed on two
different genetic backgrounds [65].
Possible causes of eye abnormalities in Le-CreTg/2;
Pax6+/+ control mice
The examples discussed above are thought to arise by action of
Cre recombinase on endogenous pseudo-loxP sites. However, the
eye abnormalities reported here for Le-CreTg/2; Pax6+/+ mice are
phenotypically very similar to those seen in Pax6+/2 heterozygotes
[19,22], which suggests that a different mechanism may be
involved. The observed reduction in Le-CreTg/2; Pax6+/+ abnor-
malities seen after crossing Le-CreTg/2 to FVB for two generations
makes it unlikely that the abnormal phenotype is caused by
permanent DNA damage of the sort expected for action of Cre
recombinase on off-target, pseudo-loxP sites. Furthermore, the
amelioration of the eye abnormalities in Le-CreTg/2; Pax6+/+ mice
by crossing to CBA/Ca-PAX77Tg/2 suggests that the mechanism
may act by affecting the dose of Pax6.
We have not investigated the mechanism underlying the Le-
CreTg/2; Pax6+/+ eye abnormalities directly but the observation
that the eyes of Le-CreTg/2; Pax6+/+; PAX77Tg/2 mice (produced
by crosses of Le-CreTg/2; Pax6fl/+ with CBA/Ca-PAX77Tg/2
transgenic mice) were less severe than in Le-CreTg/2; Pax6+/+;
PAX772/2 mice (without the PAX77 transgene) are instructive.
Firstly, crosses with Le-CreTg/2; Pax6fl/+ mice, containing both Le-
Cre and a floxed target gene, risk causing additional abnormalities
if the Le-Cre transgene is ectopically expressed in the germline (as
discussed above) but none was seen. Secondly, as the PAX77Tg/2
mice were on a CBA/Ca genetic background ($20 backcross
generations), the Le-CreTg/2; Pax6+/+; PAX77Tg/2 mice had no
less CBA/Ca genome in their genetic background but should have
higher Pax6 levels than stage-3 Le-CreTg/2; Pax6+/+ control mice
without the PAX77 transgene. The results, therefore, argue that
the eye abnormalities in our stage-3 Le-CreTg/2; Pax6+/+ mice
could be caused by a mechanism that involves Pax6 depletion.
The Le-Cre integration site remains unknown and although it is
possible that insertion of the Le-Cre transgene into the mouse
genome disrupts expression of Pax6 or a gene that affects Pax6
expression, this seems unlikely because the genetic background
effect is reversible. Also, homozygous Le-CreTg/Tg mice are viable,
so if the transgene insertion disrupted expression of an endogenous
gene it would have to specifically affect Pax6 expression and cause
eye defects without being homozygous lethal.
In our view, a more likely possibility is that expression of Cre
recombinase, from the Pax6-Le regulatory sequences in the Le-
Cre transgene, competes with the endogenous Pax6 gene for co-
factors required for Pax6 gene expression, so reducing Pax6
production from the endogenous gene. This possibility also
predicts that abnormalities observed in Le-CreTg/2; Pax6+/+ and
Le-CreTg/2; Pax6fl/+ eyes are a consequence of altered Pax6
expression in the surface ectoderm lineage. Consistent with this,
Le-CreTg/2; Pax6+/+ eye phenotypes were similar to some of the
abnormalities reported for Pax6+/2 heterozygotes [19,22] and
Eye Abnormalities in Le-Cre Mice
PLOS ONE | www.plosone.org 16 October 2014 | Volume 9 | Issue 10 | e109193
Le-CreTg/2; Pax6fl/+ phenotypes were more severe than those in
Pax6+/- mice. The types of eye abnormalities (microphthalmia plus
cataracts) reported in abstract form for Le-CreTg/Tg homozygotes
on a mixed genetic background [30] are also consistent with an
effect that is mediated via altered Pax6 levels but less penetrant on
FVB than some other genetic backgrounds. This mechanism
would predict that use of Pax6-Le regulatory sequences to drive
other transgenes (apart from Pax6 itself) would have similar
consequences on certain genetic backgrounds.
Genetic background effects on eye phenotype
Differences in genetic background also affects the phenotype of
Pax62/2 homozygotes [68] and PAX77Tg/2 transgenics [34] and
probably explains why some reported phenotypes of heterozygous
Pax6Sey/+ mice are more severe than others [47]. The existence of
variants of unknown modifier genes in different genetic back-
grounds which influence the expressivity and penetrance of
abnormal ocular phenotypes has been proposed previously to
explain genetic background effects in Le-CreTg/Tg homozygotes
(reported in abstract form [30]) and also Pax6Sey/+ or PAX77Tg/2
mice [34]. If the genetic background modulates the level or
effectiveness of Pax6, a genetic background that decreased the
effective Pax6 level is likely to increase the abnormalities in Le-
CreTg/Tg; Pax6+/+, Le-CreTg/2; Pax6+/+ and Pax6+/2 mice but
would probably reduce the severity of the abnormalities in
PAX77Tg/2 transgenic mice, which are caused by elevated levels
of Pax6.
Whatever mechanism is involved, our observation that eye
abnormalities can occur in hemizygous Le-CreTg/2 mice on some
genetic backgrounds, in the absence of a floxed allele, serves as a
cautionary tale for future studies with Le-Cre mice, almost all of
which use Le-CreTg/2 hemizygotes. Offspring with deleted floxed
alleles are analysed in most Le-Cre experiments but these are also
Le-CreTg/2 hemizygotes and are often on mixed genetic
backgrounds. Furthermore, many published Cre-loxP studies give
incomplete details about which controls are analysed or do not
include a Cre-positive control without a floxed allele. For example,
a review of studies with a different Cre transgene showed that only
6/22 (27%) included a Cre-positive control without a floxed allele
[65]. Some of the Le-Cre experiments cited in the Introduction
also failed to include this type of control and/or used Le-Cre mice
maintained on a mixed genetic background. Intriguingly, some of
these studies reported ocular phenotypes for Le-Cre-induced
conditional knockouts that appear to overlap with those seen in
our Le-CreTg/2; Pax6+/+ controls. This implies that the authors
should consider whether any of these phenotypes could have been
produced by the type of unexpected Le-Cre effects that we have
described rather than by deletion of the floxed allele. In
conclusion, our results highlight the importance of including all
the relevant controls in Cre-loxP experiments.
Supporting Information
Figure S1 Variation in eye diameter for different
genotypes on different genetic backgrounds. (A–F) Diam-
eter of left (A–C) and right (D–F) eyes of 12 week old mice from
Le-CreTg/2; Pax6+/+ and 6 Le-Cre2/2; Pax6fl/+ crosses on
different genetic backgrounds: (A,D) stage 1 crosses (B,E) stage 3
crosses (C,F) stage 4 crosses. (G–I) The percentage eye diameter
difference, calculated for each mouse as (larger eye diameter -
smaller eye diameter)6100/(larger eye diameter). Abbreviations:
WT +/+ is Le-Cre2/2; Pax6+/+; WT fl/+ is Le-Cre2/2; Pax6fl/+;
Cre +/+, Le-CreTg/2; Pax6+/+ and Cre fl/+ is Le-CreTg/2; Pax6fl/
+. Results for all four genotypes were compared by non-parametric
Kruskal-Wallis (KW) tests separately for each stage of the study (P-
values are shown in the figure) and results for WT fl/+, Cre +/+
and Cre fl/+ were compared to WT +/+ by Dunn’s multiple
comparison post-hoc test: *P,0.05; **P,0.01; ***P,0.001.
(TIF)
Figure S2 Variation in corneal diameter for different
genotypes on different genetic backgrounds. (A–F) Diam-
eter of left (A–C) and right (D–F) corneas of 12 week old mice from
Le-CreTg/2; Pax6+/+ and6Le-Cre2/2; Pax6fl crosses on different
genetic backgrounds: (A,D) stage 1 crosses (B,E) stage 3 crosses
(C,F) stage 4 crosses. (G,I) The percentage cornea diameter
difference, calculated for each mouse as (larger cornea diameter –
smaller cornea diameter) 6100/(larger cornea diameter). Abbre-
viations: WT +/+ is Le-Cre2/2; Pax6+/+; WT fl/+ is Le-Cre2/2;
Pax6fl/+; Cre +/+ is Le-CreTg/2; Pax6+/+ and Cre fl/+ is Le-CreTg/
2; Pax6fl/+. Results for all four genotypes were compared by non-
parametric Kruskal-Wallis (KW) tests separately for each stage of
the study (P-values are shown in the figure) and results for WT
fl/+, Cre +/+ and Cre fl/+ were compared to WT +/+ by Dunn’s
multiple comparison post-hoc test: *P,0.05; **P,0.01; ***P,
0.001.
(TIF)
Figure S3 Comparison of corneal epithelial wound
healing rates among different groups (from stage 2
crosses). (A–C) Mean corneal epithelial wound diameters at
different times for (A) left eyes, (B) right eyes and (C) both eyes for
each of the five groups compared. (D–H) Corneal epithelial
wound for individual corneas for (D) Le-Cre2/2; Pax6+/+ (E) Le-
Cre2/2; Pax6fl/+ (F) Le-CreTg/2; Pax6+/+ (G) Le-CreTg/2; Pax6fl/+
and (H) Pax6+/Sey-Neu. Abbreviations: WT +/+ is Le-Cre2/2;
Pax6+/+; WT fl/+ is Le-Cre2/2; Pax6fl/+; Cre +/+ is Le-CreTg/2;
Pax6+/+; Cre fl/+ is Le-CreTg/2; Pax6fl/+ and Pax6+/2 is Pax6+/Sey-
Neu.
(TIF)
Table S1 Genetic backgrounds of mice used in different
stages of the study.
(PDF)
Table S2 Frequency of healed wounds after 24 hours.
(PDF)
Supplementary Data S1 Supplementary Data for Figs. 3
& 6 and Figs. S1, S2 & S3.
(XLSX)
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